A detailed history of Bessemer Group Inc transactions in Argenx Se stock. As of the latest transaction made, Bessemer Group Inc holds 7 shares of ARGX stock, worth $4,398. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7
Holding current value
$4,398
% of portfolio
0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$434.22 - $551.9 $3,039 - $3,863
7 New
7 $4,000
Q2 2023

Aug 10, 2023

BUY
$360.14 - $422.58 $7,202 - $8,451
20 New
20 $8,000
Q3 2022

Nov 09, 2022

BUY
$343.2 - $395.75 $9,266 - $10,685
27 New
27 $10,000
Q2 2022

Aug 10, 2022

SELL
$269.58 - $378.88 $4,582 - $6,440
-17 Closed
0 $0
Q3 2021

Nov 12, 2021

SELL
$295.0 - $350.58 $885 - $1,051
-3 Reduced 15.0%
17 $5,000
Q2 2021

Aug 06, 2021

BUY
$257.11 - $319.92 $771 - $959
3 Added 17.65%
20 $6,000
Q1 2021

May 13, 2021

BUY
$268.3 - $380.31 $4,561 - $6,465
17 New
17 $4,000

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $34.8B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Bessemer Group Inc Portfolio

Follow Bessemer Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bessemer Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bessemer Group Inc with notifications on news.